From Wikipedia, the free encyclopedia
Plexxikon is an American drug-discovery company based in Berkeley, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple state-of-the-art technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 m in potential milestone payments.[1]
Pipeline
To date, the company has discovered several clinical and preclinical stage compounds.
- Zelboraf and Pexidartinib are two FDA approved drugs developed by Plexxikon
- PLX204 Plexxikon is also collaborating with Wyeth Pharmaceuticals on several products (centered on PPAR inhibitors) for use in type II diabetes and other metabolic disorders.[2] The most advanced of these agents is PLX204, which is currently in Phase 2 clinical trials for type II diabetes.[3]
References